Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 16 April 2012
(Thomson Reuters ONE) -
Kvistgård, Denmark, April 16, 2012 - Bavarian Nordic A/S (OMX: BAVA) today held
the Annual General Meeting with the results as follows:
* The Board of Directors' Report and Financial Statement for 2011 were adopted
at the General Meeting. The Board of Directors' proposal to transfer the
Company's 2011 result to next year was also adopted.
* The General Assembly adopted a resolution to discharge the Board of
Directors and the Board of Management from their obligations.
* Asger J. Aamund, Claus Bræstrup, Gerard van Odijk, Anders Gersel Pedersen
and Erik G. Hansen were re-elected to the Board of Directors. Furthermore,
Peter Kürstein was elected to the Board of Directors and will replace Erling
Johansen, who upon his own request, has chosen not to be nominated for re-
election.
* Deloitte was re-elected as auditors.
* The General Assembly adopted the Board of Directors' proposal to amend:
* Article 5a of the Articles of Association into two separate
authorisations (Articles 5a(1) and 5a(2)) as well as to increase and
extend the two authorisations so that the Board of Directors overall is
authorised to increase the share capital of the Company with a total of
nominally DKK 26,000,000 until 30 June 2013.
* Article 5b of the Articles of Association (Authorization for issuing
Warrants to the management and employees et. al.)
* Article 5h of the Articles of Association to take up a loan against
convertible notes.
* The General Assembly approved the suggested remuneration of the Board of
Directors for the current financial year.
* The Board of Directors were given authorization to let the Company purchase
its own shares of company stock in the period up to the next Annual General
Meeting.
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC(®), a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC(®) has been tested
in nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE(®), a third-generation smallpox vaccine candidate that is being
developed and supplied for emergency use to the U.S. Strategic National
Stockpile under a contract with the U.S. Government. For more information, visit
www.bavarian-nordic.com
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201206uk:
http://hugin.info/100065/R/1602617/506408.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1602617]
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2012 - 19:24 Uhr
Sprache: Deutsch
News-ID 135434
Anzahl Zeichen: 4729
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 16 April 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
